{
    "symbol": "IRWD",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-08 03:58:05",
    "content": " Building that last year\u2019s momentum, LINZESS prescription demand increased an impressive 11% year-over-year in the first quarter of 2022 as shown on Slide 8 continuing the stretch of five consecutive quarters of double-digit prescription demand growth. Your line is open. And so given the colonic action of linaclotide that we know of, we\u2019re first testing the rectal administration of IW-3300 just to ensure we have an adequate dose to prove this hypothesis because we will know with the rectal administration that we\u2019re getting adequate exposure, so we certainly feel like we can achieve the dose we need, the cost of hypothesis proves to be valid to show a real clinical improvement in the pain sensation and bladder pain syndrome patients because there is a lot of epidemiologic data that sort of correlates with IBS and bladder pain syndrome. Your line is open. Your line is open. Your line is open."
}